(Q37187386)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542119%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

review article

1 reference

title

Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542119%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542119%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Francesco Pantano

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542119%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Daniele Santini

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542119%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Giuseppe Tonini

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542119%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

2

Gaia Schiavon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542119%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

10 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542119%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Oncology

8 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542119%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542119%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542119%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

455-465

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18542119%20AND%20SRC:MED&resulttype=core&format=json

Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

Recurrent episodes of involuntary masticatory spasms induced by continuous infusion of oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

Understanding the cancer biology universe: enigmas, context and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

21 January 2018

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Molecular predictors of survival after adjuvant chemotherapy for colon cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Irinotecan in the treatment of colorectal cancer: clinical overview

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Influence of sex and age on fluorouracil clearance

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Impact of diabetes mellitus on outcomes in patients with colon cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy*

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Role in translation of a triple tandemly repeated sequence in the 5'-untranslated region of human thymidylate synthase mRNA.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Functional Analysis and DNA Polymorphism of the Tandemly Repeated Sequences in the 5'-terminal Regulatory Region of the Human Gene for Thymidylate Synthase

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Novel thymidylate synthase enhancer region alleles in African populations

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Biological and clinical implications of the MTHFR C677T polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF)

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

The current status of camptothecin analogues as antitumor agents

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Phase I study of oxaliplatin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Clinical management of oxaliplatin-associated neurotoxicity.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Oxaliplatin: a review of preclinical and clinical studies.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Fatal liver failure after the administration of raltitrexed for cancer chemotherapy: a report of two cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021

Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC1137

7 January 2021